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SUBJECT AREA 33 
Environmental and Exercise Physiology 34 
NEW FINDINGS: 35 
What is the central question(s) of this study?  36 
To assess the reliability of gastrointestinal barrier integrity and microbial translocation 37 
biomarkers both at rest and in response to exertional-heat stress.  38 
What is the main finding and its importance? 39 
Acceptable and defined-levels of reliability are presented for the serum Dual-Sugar 40 
Absorption (lactulose/L-rhamnose) Test, Intestinal Fatty-Acid Binding Protein, Claudin-3, 41 
Lipopolysaccharide Binding Protein, total 16s DNA, but not the Bacteroides/total 16s DNA 42 
ratio at both measurement time-points.  43 
  44 
ABSTRACT 45 
Purpose: Exertional-heat stress adversely distrupts (GI) barrier integrity and, through 46 
subsequent microbial translocation (MT), negativly impacts health. Despite widespread 47 
application, the temporal reliability of popular GI barrier integity and MT biomarkers is poorly 48 
characterised. Method: Fourteen males completed two 80-minute exertional-heat stress 49 
tests (EHST) separated by 7-14 days. Venous blood was drawn pre, immediately- and 1-hour 50 
post both EHSTs. GI barrier integrity was assessed using the serum Dual-Sugar Absorption 51 
Test (DSAT), Intestinal Fatty-Acid Binding Protein (I-FABP) and Claudin-3 (CLDN-3). MT was 52 
assessed using plasma Lipopolysaccharide Binding Protein (LBP), total 16S bacterial DNA and 53 
Bacteroides DNA. Results: No GI barrier integrity or MT biomarker, except absolute 54 
Bacteroides concentration, displayed systematic trial order bias (p ≥ 0.05). I-FABP (trial 1 = Δ 55 
0.834 ± 0.445 ng·ml-1; trial 2 = Δ 0.776 ± 0.489 ng·ml-1) and CLDN-3 (trial 1 = Δ 0.317 ± 0.586 56 
ng·ml-1; trial 2 = Δ 0.371 ± 0.508 ng·ml-1) were increased post-EHST (p ≤ 0.01). All MT 57 
biomarkers were unchanged post-EHST. Coefficient of variation and typical error of 58 
measurement post-EHST were: 11.5% and 0.004 (ratio) for the DSAT 90-minutes post probe 59 
ingestion; 12.2% and 0.004 (ratio) at 150-minutes post probe ingestion; 12.1% and 0.376 60 
ng·ml-1 for I-FABP; 4.9% and 0.342 ng·ml-1 for CLDN-3; 9.2% and 0.420 µg·ml-1 for LBP; 9.5% 61 
and 0.15 pg·µl-1 for total 16S DNA; and 54.7% and 0.032 for Bacteroides/total 16S DNA ratio. 62 
Conclusion: Each GI barrier integrity and MT translocation biomarker, except 63 
Bacteroides/total 16S ratio, had acceptable reliability at rest and post exertional-heat stress. 64 
 65 
  66 
ABBREVIATIONS 67 
ANOVA Analysis of variance 68 
B-A  Bland-Altman Limits of Agreement 69 
Bact.  Bacteroides 70 
BactDNA Bacterial DNA 71 
CLDN-3 Claudin-3 72 
CV  Coefficient of Variation 73 
DSAT  Dual Sugar Absorption Test 74 
EDTA  Ethylenediaminetetraacetic acid 75 
EHST  Exertional Heat Stress Test 76 
ELISA  Enzyme Linked Immunosorbent Assay 77 
GI  Gastrointestinal 78 
HPLC  High Performance Liquid Chromatography 79 
HR  Heart Rate 80 
I-FABP  Intestinal Fatty-Acid Binding Protein 81 
ISAK International Society for the Advancement of Anthropometric 82 
Kinanthropometry 83 
LBP  Lipopolysaccharide Binding Protein 84 
L/R  Lactulose-to-Rhamnose 85 
MT  Microbial Translocation 86 
PCR  Polymerase Chain Reaction 87 
RH  Relative Humidity 88 
RPE  Rate of Perceived Exertion 89 
SD  Standard Deviation 90 
Tcore  Core Body Temperature 91 
Tbody  Mean Body Temperature 92 
TEM  Typical Error of Measurement 93 
Tskin  Mean Skin Temperature 94 
TS  Thermal Sensation 95 
V̇O2max  Maximal Oxygen Uptake 96 
  97 
INTRODUCTION 98 
The gastrointestinal (GI) microbiota is a complex microbial ecosystem, which performs 99 
numerous functions symbiotic to human health (Cani, 2018). However, to prevent immune 100 
activation the microbiota must remain contained within the GI lumen, a process that is tightly 101 
regulated by the multi-layered GI barrier (Wells et al., 2017). Exertional heat stress is one 102 
stimulus that adversely disrupts GI barrier integrity, and in a linear manner to the severity of 103 
splanchnic hypoperfusion (van Wijck et al., 2011) and core body temperature (Pires et al., 104 
2017). In severe cases, luminal microbial products are capable of transversion into the 105 
systemic circulation, a response now considered to underlie multiple common athletic health 106 
conditions (Costa et al., 2017). Specifically, the most concerning of these health conditions 107 
include exercise-induced anaphylaxis (Christensen et al., 2019) and exertional heatstroke 108 
(Lim, 2018). In non-exercise settings, research presently links GI microbial translocation (MT) 109 
within the pathophysiology of numerous chronic illnesses, including GI disease (Camilleri et 110 
al., 2012), cardiovascular disease (Neves et al., 2013) and degenerative disorders of the 111 
central nervous system (Mulak and Bonaz, 2015). Thus, reliable biomarkers of GI barrier 112 
integrity and/or MT appear important in the surveillance, diagnosis and treatment of these 113 
conditions. To date, there is little evidence documenting the reliability of most commonplace 114 
assessment biomarkers, which limits interpretation of their application in both laboratory and 115 
field settings. 116 
GI barrier integrity can be assessed in vivo using several biomarkers of intestinal 117 
permeability, epithelial injury and tight junction integrity (Wells et al., 2017). The Dual-Sugar 118 
Absorption Test (DSAT) is the gold-standard GI permeability technique (Bischoff et al., 2014). 119 
The traditional endpoint of the DSAT is the 5-hour urinary recovery of pre-ingested lactulose-120 
to-L-rhamnose (L/R; Bischoff et al., 2014) and offers good test-retest reliability when applied 121 
at rest (Marchbank et al., 2011). Analytical improvements have recently validated a serum 122 
DSAT over a reduced (i.e. 1-3 hours) time course (van Wijck et al., 2013) and with improved 123 
diagnostic sensitivity (JanssenDuijghuijsen et al., 2016; Pugh et al., 2017a). However, given 124 
the transient appearance of sugar probes within the blood (Fleming et al, 1996), potentially 125 
due to the wide heterogeneity in gastric emptying rates following exercise (Costa et al., 2017), 126 
the reliability of this technique requires verification. Intestinal Fatty Acid-Binding Protein (I-127 
FABP) is a cytosolic protein expressed exclusively within enterocytes of the 128 
duodenum/jejunum, and has a half-life of 11 minutes in the systemic circulation following 129 
epithelial injury (van de Poll et al. 2007). These characteristics have popularised I-FABP as a 130 
prominent biomarker of small GI epithelial injury (Wells et al., 2017), with serum 131 
concentrations strongly predictive of small GI histological injury (Schellekens et al., 2014). The 132 
temporal reliability of I-FABP has never been directly assessed and requires interrogation 133 
given its high sensitivity to sub-clinical small GI injury. Claudin-3 (CLDN-3) is a conserved GI 134 
epithelial transmembrane protein, which performs an integral role in GI paracellular 135 
homeostasis (Zeissig et al., 2007). As a biomarker of GI tight junction (TJ) integrity, preliminary 136 
research has shown a strong relationship between urinary CLDN-3 concentration and 137 
histological GI CLDN-3 breakdown (Thuijls et al., 2010a, 2010b). Similar to I-FABP, the 138 
temporal reliability of plasma CLDN-3 is currently unknown.  139 
GI MT can be assessed in vivo through several indirect biomarkers considered to be 140 
indicative of systemic microbial exposure (Wells et al., 2017). Endotoxin, a form of 141 
lipopolysaccharide located on the outer membrane of gram-negative bacteria, has 142 
traditionally been utilised for this purpose (Costa et al., 2017). However, the search for 143 
improved GI MT biomarkers is ongoing, given endotoxin analysis is susceptible to both false-144 
positive (e.g. from exogenous contamination) and false-negative (e.g. from rapid hepatic 145 
clearance) results (Dullah and Ongkudon, 2017). Lipopolysaccharide binding protein (LBP) is 146 
a type-1 acute phase protein, secreted hepatically following systemic exposure to numerous 147 
microbial-associated molecular patterns (Schumann, 2011). However, as an acute-phase 148 
protein, its temporal reliability is likely highly subject to influence from numerous co-variates 149 
(e.g. infection) (Citronberg et al., 2016). Bacterial DNA (bactDNA), through conserved 16S 150 
gene sequencing, is an emerging biomarker of GI MT (Paisse et al., 2016). In comparison with 151 
alternative MT measures, one major advantage of bactDNA is an apparent independence of 152 
hepatic clearance (Mortensen et al., 2013). One innovative study recently proposed a 153 
bactDNA methodology aimed to improve analytical specificity and reliability through 154 
targeting a predominant GI bacterial genus (Bacteroides) and correcting for total 16S DNA 155 
concentration (March et al., 2019).  156 
 157 
The aim of the present study was to determine the reliability of biomarkers of GI 158 
barrier integrity (DSAT, I-FABP, CLDN-3) and microbial translocation (LBP, total 16s bacterial 159 
DNA, Bacteroides DNA) at rest and following exertional-heat stress. These data should inform 160 
prospective study design, including biomarker selection and statistical power. 161 
METHODS 162 
Participants and Ethical Approval 163 
Fourteen healthy males (Table 1) volunteered to participate in the present study. All 164 
participants were non-smokers, habitually active, non-endurance trained (>4 h·week-1) and 165 
unacclimated to hot environments. A general medical questionnaire was used to screen for 166 
previous histories of gastrointestinal, cardiorespiratory and metabolic illnesses. No 167 
participant took pharmacological medications (e.g. laxatives, antibiotics) or reported 168 
suffering from an acute illness within 14 days prior to data collection. Informed consent was 169 
obtained for each participant following a full written and oral explanation of the experimental 170 
procedures. The study protocol was approved by Plymouth MARJON University Research 171 
Ethics Committee (Approval Code: EP040) and was conducted in accordance with the 172 
principles outlined in the Declaration of Helsinki, except for trial registration within a 173 
database. 174 
[Table 1 – Insert Here] 175 
Experimental Overview 176 
Participants visited the laboratory on three occasions. During the first visit, baseline 177 
anthropometrics and maximal oxygen uptake (V̇O2max) were assessed. The second and third 178 
visits were the main experimental trials. These were separated by 7-14 days to negate the 179 
influence of prior exertional-heat stress on thermoregulatory (Barnett and Maughan, 1993) 180 
and GI barrier integrity (Snipe et al., 2017) responses. During both main experimental trials, 181 
participants completed an intermittent exertional-heat stress test (EHST), consisting of two 182 
bouts of 40 minutes fixed-intensity treadmill walking (6 km·h-1 and 7% gradient) in the heat 183 
(35°C and 30% relative humidity; RH). The exercise bouts were separated by 20-minutes 184 
seated recovery, including 4-minutes forearm cold water immersion. This protocol is 185 
consistent with general military guidance on work/rest schedules for sustained physical 186 
activity in the heat (Military Headquarters of the Surgeon General, 2017) and unpublished 187 
pilot data from our laboratory showing a ~ 2-fold elevation in DSAT responses relative to rest 188 
(n= 6; DSAT 90-minute post probe ingestion; [rest] = 0.014 ± 0.006, [post EHST] = 0.028 ± 189 
0.005; p = 0.02). Data collection coincided with non-summer months in Plymouth, United 190 
Kingdom, where daily mean ambient temperature at a local meteorological station 191 
(Camborne, United Kingdom; latitude: 50.218 ° N) remained below 20°C (Met Office, 2019). 192 
A schematic illustration of the protocol is shown in Figure 1. 193 
 194 
[Figure 1 – Insert Here] 195 
 196 
Dietary and Lifestyle Controls 197 
Dietary supplementation (e.g. glutamine, probiotics, bovine colostrum) and prolonged 198 
thermal exposures (e.g. saunas, sunbeds) were prohibited from 14 days before until the end 199 
of data collection (Costa et al., 2017). Alcohol, caffeine, strenuous physical activity and non-200 
steroidal anti-inflammatory drugs (e.g. ibuprofen) were all abstained for 48 hours before main 201 
experimental visits (Costa et al., 2017). Participants adhered to a ≥ 10 hour overnight fast and 202 
consumed 500 ml of plain water two hours prior to main experimental visits. Conformity with 203 
all pre-trial controls was assessed in writing upon laboratory arrival using a pre-trial control 204 
questionnaire. Participants remained fasted throughout all main experimental trials 205 
(Edinburgh et al., 2018), but were permitted a 12 ml·kg-1 bolus of ambient temperature water 206 
(28-30°C) to drink over 20 minutes following both 40-minute EHST bouts. 207 
Anthropometric Measurements 208 
Participants height, weight and body fat were measured following ISAK guidelines 209 
(Marfell-Jones et al. 2006). Height was measured barefoot using a stadiometer to the nearest 210 
0.1 cm (Marsden HM-200, Rotherham, UK), whilst body mass was measured on an electronic 211 
scale to the nearest 0.05 kg (Tanita MC 180 MA, Tokyo, Japan). Skinfold thicknesses were 212 
taken in duplicate by the same researcher at the bicep, tricep, subscapular and suprailliac 213 
using skinfold callipers to the nearest 0.1 cm (Harpenden, Holtain Ltd, Crymych, UK). 214 
Predictions of body density were calculated using age and gender related equations (Durnin 215 
and Womersley, 1974). 216 
Maximal Oxygen Uptake 217 
Maximal oxygen uptake (V̇O2max) was determined using an incremental treadmill test 218 
(Desmo HP, Woodway GmbH, Weil am Rhein, Germany) to volitional exhaustion. The test was 219 
undertaken in normothermic laboratory conditions (18-22°C, 40-60% RH). The test began at 220 
a speed of 10 km·h-1 on a fixed 1% inclination. The treadmill speed was then increased at 1 221 
km·h-1 increments every three minutes until reaching 13 km·h-1, when inclination was then 222 
increased by 2% every two minutes. Expired metabolic gases were measured continuously 223 
using a breath-by-breath metabolic cart (Metalyser 3B, Cortex, Leipzig, Germany). Heart rate 224 
(HR; Polar FT1, Polar Electro OY, Kempele, Finland) and rating of perceived exertion (RPE; 225 
Borg, 1970) were measuring during the final ten seconds of each stage. The highest 30 second 226 
average V̇O2 was taken to be V̇O2max.  227 
Exertional-Heat Stress Test 228 
EHSTs commenced in the morning (08:30 ± 1 hour) to avoid the influence of circadian 229 
variation (Waterhouse et al., 2005). Upon laboratory arrival, participants provided a capillary 230 
blood sample into a K2EDTA microtube (Microvette®, Sarstedt, Numbrecht, Germany) for 231 
duplicate hydration assessment via plasma osmolality using freeze-point depression 232 
(Osmomat 3000, Gonotec, Berlin, Germany). Participants then measured their own nude 233 
body mass (Tanita MC 180 MA, Tokyo, Japan). They then self-inserted a single use rectal 234 
thermistor (Tcore; Phillips 21090A, Guildford, UK) 12 cm beyond the anal sphincter and a HR 235 
monitor was positioned around their chest (EQ02, Equivital™, Cambridge UK). Next they 236 
dressed in standard summer military clothing (i.e. jacket [zipped, sleeves extended], trousers, 237 
boxer briefs, socks, trainers) and entered the environmental chamber that was regulated at 238 
~35°C (Trial 1: 35.2 ± 0.3°C; Trial 2: 35.4 ± 0.4°C; p= 0.15) and ~30% RH (Trial 1: 28 ± 4%; Trial 239 
2: 28 ± 2%; p= 0.25). Skin thermistors (EUS-UU-VL3-O, Grant Instruments, Cambridge, UK) 240 
were then affixed on the participant using one layer (5 x 5 cm) of cotton tape (KT Tape®, KT 241 
Health, UT, USA) and mean skin temperature (Tskin) was calculated using standard equations 242 
(Ramanathan, 1964).  243 
Participants then undertook the pre-defined EHST. Throughout, Tcore and Tskin were 244 
recorded using a temperature logger (Squirrel SQ2010, Grant Instruments, Cambridge, UK) 245 
and HR using a Sensor Electronics Module (SEM) unit (EQ02, Equivital™, Cambridge UK). Mean 246 
whole body temperature (Tbody) was calculated from simultaneous Tcore and Tskin 247 
measurements (Jay and Kenny, 2007). All data, including RPE (Borg et al., 1970) and thermal 248 
sensation (TS; Toner et al., 1986) were reported at 20 minute intervals. Between the two 249 
walking bouts, participants immersed their forearms in a ~15°C cold-water bath (Trial 1: 15.4 250 
± 0.8°C, Trial 2: 15.3 ± 0.7°C; p = 0.39). Upon EHST termination, participants were removed 251 
from heat and their post-EHST nude body mass was recorded. Absolute sweat losses were 252 
calculated from the change in dry nude body mass from pre-to-post EHST after correction for 253 
fluid intake and blood withdrawal.  254 
Blood Collection and Analysis 255 
Venous blood samples (12 ml) were drawn immediately pre, post and one-hour post 256 
EHST. Participants stood upright for a minimum of 20 minutes before collection to allow 257 
capillary filtration pressure to stabilise (Shirreffs and Maughan, 1994). Blood was drawn from 258 
a forearm antecubital vein under minimal stasis (<30 seconds). Samples were collected 259 
proportionally into serum-separator (SST II) and K2 EDTA tubes (Becton Dickinson and 260 
Company, Plymouth, UK). The SST II tube was allowed to clot for 30-40 minutes at room 261 
temperature. A 0.5ml aliquot of K2EDTA blood was removed for immediate haematological 262 
analysis. Samples were centrifuged at 1300g for 15 minutes at 4°C to separate serum and 263 
plasma. Aliquots were frozen at -80°C until analyses. All blood handling was performed with 264 
sterile (pyrogen, DNA free) pipette tips and microtubes.  265 
Haematology 266 
Haemoglobin was measured in duplicate using a portable photometric analyser 267 
(Hemocue® Hb 201+, EFK Diagnostics, Madeburg, Germany; Duplicate) and haematocrit in 268 
duplicate using the microcapillary technique following centrifugation at 14,000g for 4 minutes 269 
at room temperature (Haematospin 1400, Hawksley and Sons Ltd, Lancing, England). Plasma 270 
volume was estimated using standard equations (Dill and Costill, 1974). Post-exercise analyte 271 
concentrations were left uncorrected for acute plasma volume shifts, given the similarity of 272 
responses between trials and the low molecular weights of quantified analytes.  273 
Dual-Sugar Absorption Test 274 
Participants orally ingested a standard sugar probe solution containing 5 g Lactulose 275 
(Lactulose Oral Solution, Sandoz, Holzkirchen, Germany) and 2 g L-Rhamnose (L-rhamnose FG, 276 
99% pure, Sigma Aldrich, Missouri, USA) dissolved within 50 ml of plain water (osmolality = 277 
~750 mOsm·kg-1) ten minutes into the EHST. Probe concentrations were determined from 278 
serum samples collected immediately pre, 90 minutes (i.e. post-EHST) and 150 minutes (i.e. 279 
1-hour post-EHST) post probe ingestion following a previously described high performance 280 
liquid chromatography protocol (Fleming et al., 1996). The recovery of both sugars was 281 
determined per litre serum (mg·l-1). Calculation of the L/R ratio was made corrected relative 282 
(%) to the concentration of sugar consumed. The limit of detection was 0.1 mg·l-1 and the 283 
laboratory reference coefficient of variation was 1.8-8.5% for both probes (Fleming et al., 284 
1996). 285 
Enzyme Linked Immunosorbent Assays 286 
I-FABP ([1:2 serum dilution]; ELH-FABP2, Raybiotech®, Norcross, USA), CLDN-3 287 
([undiluted plasma]; EH1342, Wuhan Fine Biotech, Wuhan, China) and LBP ([1:250 plasma 288 
dilution]; RK01764, ABcloncal, Wuburn, USA) were measured in duplicate immediately pre 289 
and post EHST using a solid-phase sandwich ELISA. Optical density was measured at 450 nm 290 
using a microplate reader and sample concentrations were determined from a logarithmic 291 
standard curve. The intra-assay coefficients of variation were 5.0% (I-FABP), 1.5% (CLDN-3) 292 
and 2.6% (LBP).  293 
Quantitative Real-Time Polymerase Chain Reaction 294 
BactDNA was measured in duplicate plasma samples collected immediately pre- and 295 
post EHST using a quantitative real-time polymerase chain reaction assay (qPCR) on a 296 
LightCycler 96 instrument (LightCycler 96, Roche, Basel, Switzerland). Cell free DNA was 297 
isolated from plasma using a Quick-DNA Mini Prep Plus kit (D4068, Zymo Research, Irvine, CA, 298 
USA) following manufacturer’s instructions. Total 16S bacterial DNA was quantified according 299 
to March et al. (2019) using a universal library probe (ULP, Roche, Basel, Switzerland), with 300 
standards (E2006-2, Zymo Research, Irvine, CA, USA) and primers (Eurogentec, Liège, 301 
Belgium) specific to a 16S region (limit of detection 0.1 pg·ul-1). Bacteroides species DNA 302 
(Bact. DNA) were quantified using a double-dye probe/primer kit (Path-Bacteroides-spp, 303 
Genesig, Primerdesign Ltd, Chandler’s Ford, UK). Negative controls (PCR grade water) for the 304 
entire extraction process were below the limit of detection for both measures. Ratio data are 305 
presented as Bacteroides/total bacterial DNA (Bact./16S). The intra-assay coefficients of 306 
variation were 6.3% (total 16S) and 17.5% (Bacteroides). 307 
Statistics 308 
All statistical analyses were performed using Prism Graphpad software (Prism V.8, La 309 
Jolla, California, USA). Comparisons were made after determining normal distribution using a 310 
Shapiro-Wilk test (p ≥ 0.05). A two-way analysis of variance (ANOVA) with repeated measures 311 
(time x trial) was used to identify differences between the two trials for whole-body 312 
physiological, GI barrier integrity and MT data. If Mauchly’s test for sphericity was violated, 313 
Greenhouse Geiser corrections were applied for epsilon <0.75, while the Huynh-Feldt 314 
correction was used for less severe asphericity. When there was only a single comparison, a 315 
paired t-test or non-parametric Wilcoxon signed-ranks test was used to determine between-316 
trial differences. Statistical significance was accepted at the alpha level of p ≤ 0.05. Data are 317 
presented as mean ± standard deviation (SD). 318 
A composite a priori battery of statistical tests was conducted to determine inter-trial 319 
reliability (Atkinson and Nevill, 1998). The DSAT was compared at each 90- and 150-minutes 320 
following sugar-probe ingestion, whilst each GI biomarker was compared at rest, post EHST 321 
and the delta (Δ). Systematic bias was assessed using a paired t-test or non-parametric 322 
Wilcoxon signed-ranks test. Meaningful differences were evaluated using Cohen’s d (Lakens, 323 
2013). Effect sizes were categorised as trivial (≤0.19), small (0.20-0.49), medium (0.50-0.79) 324 
and large (≥0.8). Relative reliability was assessed using a Pearson’s product-moment 325 
correlation coefficient or non-parametric Spearman’s rank correlation coefficient. 326 
Correlations were classified as small (≤0.69), moderate (0.70-0.89) and high (≥0.90) (Vincent 327 
and Weir, 1995). Absolute reliability was assessed using each the: coefficient of variation 328 
([SD/mean]*100), typical error of the measurement (TEM; SD of difference between 329 
scores/√2) and Bland-Altman (B-A) plots with mean difference (bias) and 95 % Limits of 330 
Agreement (LoA; Bland and Altman, 1986). CVs were classified as very good (≤ 10%) and 331 
acceptable (≤ 20%). Relationships between biomarkers were compared using a Pearson’s 332 
product-moment correlation coefficient or non-parametric Spearman’s rank correlation 333 
coefficient. Heteroscedasticity was examined from the non-parametric correlational 334 
coefficient between absolute differences and individual means presented on B-A plots. 335 
Outliers were defined as ± 2.4 SD units (normally distributed) or ± 4.0 SD units (non-normally 336 
distributed) outside of the mean and were removed from subsequent analysis (Aguinis et al., 337 
2013).  338 
Power Analysis 339 
Given the novelty of the dependent variables being evaluated and statistical approach 340 
to undertake a battery of reliability statistical tests, it was determined infeasible to perform 341 
an a priori sample size calculation. Instead, general guidance on appropriate sample sizes (n 342 
= 12) for pilot studies were followed, whilst accounting for a ~20% anticipated participant 343 
drop-out rate (Julious, 2005). 344 
 345 
RESULTS 346 
Thermoregulatory, Cardiovascular and Perceptual Strain 347 
Tcore (Figure 2A; time x trial p = 0.63), Tskin (Figure 2B; time x trial p = 0.13) and Tbody 348 
(Figure 2C; time x trial p = 0.43) all increased over time to a similar extent between trial one 349 
and two. The reliability of peak, mean and Δ in Tcore, Tskin and Tbody were all good (Table 2). 350 
Pre-trial plasma osmolality (trial one: 293 ± 7 mOsmol·kg-1, trial two: 294 ± 7 mOsmol·kg-1; p 351 
= 0.67), Δ plasma volume (trial 1: -0.61 ± 5.15%, trial 2: -0.02 ± 3.69%; p = 0.67), mean sweat 352 
rate (trial 1: 1.53 ± 0.38, trial 2: 1.56 ± 0.45 l·h-1; p = 0.61) and percentage body mass loss (trial 353 
1: 1.15 ± 0.48; trial 2: 1.21 ± 0.52%; p = 0.31) were all similar between trial one and two. HR 354 
(Figure 2D; time x trial p = 0.11), RPE (Figure 2E; time x trial p = 0.38) and TS (Figure 2F; time 355 
x trial p = 0.56) all increased over time to a similar extent between trial one and two. The 356 
reliability of peak, mean and Δ HR, RPE and TS were all good (Table 2). 357 
 358 
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 363 
Dual-Sugar Absorption Test 364 
 Lactulose and L-rhamnose were both undetectable in all participants’ basal sample 365 
prior to probe ingestion. Inter-trial DSAT responses displayed no systematic bias between 366 
trials at both 90- (Figure 3A) and 150-minutes (Figure 3C). There was moderate relative 367 
reliability and acceptable absolute reliability at both the 90- and 150-minute time-points. B-A 368 
plots displayed bias for both the 90- (Figure 3B) and 150-minute (Figure 3D) time-points. 369 
Individual Lactulose and L-rhamnose concentrations had worse reliability than the combined 370 
L/R ratio (Table 3). Heteroscedasticity was not present for any analyses.  371 
Intestinal Fatty Acid Binding Protein 372 
 I-FABP displayed no trial order systematic bias at either rest, post- or the Δ time-point 373 
(Figure 3E).  Following EHSTs, I-FABP was elevated above rest (trial 1: Δ = 0.834 ± 0.445 ng·ml-374 
1 [56 ± 31%]; trial 2: Δ = 0.776 ± 0.489 ng·ml-1 [46 ± 26%]; p ≤ 0.01; Figure 3E). At all time-375 
points, I-FABP displayed moderate relative and acceptable absolute reliability (Table 3). B-A 376 
plots are presented to illustrate bias for post EHST concentrations (Figure 3F). 377 
Heteroscedasticity was not present for any analyses. One participant was excluded as an 378 
outlier. Two participants’ I-FABP responses displayed unexplainably poor reliability both at 379 
rest and post EHSTs. These data were retained given where verbal adherence to pre-trial 380 
controls was verbally confirmed. However, removal of these data would have notably 381 
improved the reliability of I-FABP both at rest (r = 0.97; CV = 6.1%; TEM = 0.200 ng·ml-1; B-A ± 382 
LoA = -0.046 ± 0.308 ng·ml-1) and post the  EHST (r = 0.97; CV = 7.2%; TEM = 0.221 ng·ml-1; B-383 
A ± LoA = 0.078 ± 0.467 ng·ml-1).  384 
Claudin-3 385 
 CLDN-3 displayed no trial order systematic bias at either rest, post- or the Δ time-point 386 
(Figure 3G). Following EHSTs CLDN-3 was elevated above rest (trial 1: Δ = 0.317 ± 0.586 ng·ml-387 
1 [11 ± 17%]; trial 2: Δ = 0.371 ± 0.508 ng·ml-1 [9 ± 13%]; p ≤ 0.01; Figure 3G). At all time-points, 388 
CLDN-3 displayed high relative and very good absolute reliability (Table 3). B-A plots are 389 
presented to illustrate bias for post EHST concentrations (Figure 3H). Heteroscedasticity was 390 
not present for any analyses.  391 
 392 
 [Table 3 – Insert Here] 393 
 394 
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 396 
Lipopolysaccharide Binding Protein  397 
 LBP displayed no trial order systematic bias at either rest, post EHSTs or the Δ time-398 
point (Figure 4A). There was no influence of the EHST on LBP concentration (p = 0.41). At all-399 
time-points, LBP displayed moderate relative and very good absolute reliability (Table 4). B-A 400 
plots are presented to illustrate bias for post EHST concentrations (Figure 4B). 401 
Heteroscedasticity was not present for any analyses.  402 
 403 
 404 
Bacterial DNA 405 
Total 16s (Figure 4C) and Bact./16S (Figure 4G) displayed no systematic bias at either 406 
rest, post EHSTs or the Δ. Bacteroides concentrations (Figure 4E) were systematically lower in 407 
trial 2 versus trial 1 (p = 0.04). At rest, total 16s displayed moderate relative and very good 408 
absolute reliability, whereas Bacteroides displayed poor relative and absolute reliability. The 409 
combined Bact./16S ratio subsequently showed poor relative and absolute reliability at rest 410 
(Table 4). There was no influence of the EHST on either total 16s (p = 0.39), Bacteroides (p = 411 
0.33) or Bact./16S (p = 0.18) responses. B-A plots are presented to illustrate bias for post EHST 412 
concentrations (Figure 4D, 4F and 4H). Heteroscedasticity was not present for any analyses. 413 
One participant was excluded from all bactDNA analysis as an outlier.   414 
 415 
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 418 
Association between Biomarkers 419 
Validation of the DSAT at the 90 and 150- minutes time-points across both trial one 420 
and trial two (n=28), found responses to be systematically greater at 150- (0.034 ± 0.015) 421 
compared with 90-minutes (0.027 ± 0.013; p = 0.05, ES 0.50). There was poor relative (r = 422 
0.08) and absolute (CV = 31.8%, TEM = 0.014) reliability between the sample time-points, 423 
suggestive of inter-individual variability in sugar probe kinetics. Few statistically significant 424 
correlations were reported when comparing GI barrier integrity and MT biomarkers. Small 425 
positive correlations were reported between absolute post EHST concentrations for: I-FABP 426 
and CLDN-3 (r = 0.41, p = 0.04), LBP and total 16s DNA (r = 0.48, p = 0.02), LBP and Bacteroides 427 
(r = 0.38; p = 0.05), Bacteroides and total 16s DNA (r = 0.40, p = 0.04). When displayed as pre-428 
to-post DELTA, small positive correlations were reported between: LBP and DSAT at 150 429 
minutes (r = 0.54; p < 0.01). 430 
 431 
DISCUSSION 432 
The aim of this study was to determine the short-term (one-two weeks) temporal 433 
reliability of several empirical biomarkers of GI barrier integrity (DSAT, I-FABP, CLDN-3) and 434 
MT (LBP, total 16s bacterial DNA, Bacteroides DNA) following exertional-heat stress. The main 435 
findings of this study were that the serum DSAT, I-FABP, CLDN-3, LBP and total 16s bacterial 436 
DNA all displayed moderate-to-strong relative and acceptable absolute reliability between 437 
repeat EHSTs. In comparison, absolute Bacteroides DNA and Bact./total 16s DNA ratio 438 
displayed weak relative and unacceptable absolute reliability between repeat EHSTs.  439 
 The serum DSAT is a valid alternative of the traditional urine DSAT (Fleming et al, 1996; 440 
van Wijck et al., 2011), which offering improved sensitivity to detect transient losses in GI 441 
barrier integrity following exercise (JanssenDuijghuijsen et al., 2016; Pugh et al., 2017a). 442 
Despite this, the temporal reliability of the serum DSAT has never been previously assessed. 443 
Potential sources of variability with the serum DSAT might relate to both the transient time 444 
course of sugar probes in the blood and low absolute lactulose concentrations that challenge 445 
the detection limits of common analytical techniques (Fleming et al., 1996; van Wijck et al., 446 
2013). In this study, we show for the first time that the serum DSAT can be utilised with 447 
acceptable reliability, which is comparative to that previously reported with the urine DSAT 448 
over both a three-day (van Elburg et al. 1995) and two-week period (Marchbank et al., 2011). 449 
The optimal time-point for blood collection with the serum DSAT is an unresolved issue that 450 
concerns the methodological implementation of this measure. Herein, blood was collected at 451 
both 90-minutes post probe ingestion as this provides the most valid estimate of the urine 452 
DSAT in basal conditions (Fleming et al., 1996), and at 150-minutes post as this is where peak 453 
responses arose following similar exercise stress (van Wijck et al., 2011). Remarkedly, the 454 
temporal reliability of both time-points assessed was almost identical, though given large 455 
inter-individual variation in probe kinetics, the magnitude of responses at the two time-points 456 
had poor validity. Together, these findings advocate the use of the serum DSAT at either 90- 457 
or 150- minutes following probe ingestion (where logistically most convenient) as a reliable 458 
alternative to the urine DSAT. There appears little requirement to correct for basal sugar 459 
probe concentrations (pre-probe ingestion) following a ≥ 10 hour overnight fast given that all 460 
participants samples were returned negative.  461 
I-FABP is the principal biomarker of GI epithelial injury (Wells et al., 2017). Despite 462 
growing popularity, the temporal reliability of circulating I-FABP has never been previously 463 
assessed. In the present study, resting I-FABP concentrations were consistently at the upper 464 
end of the general healthy reference range for studies utilising an human ELISA kit (0.1-2.0 465 
ng·ml-1; Treskes et al., 2017). These concentrations must be considered when evaluating the 466 
absolute reliability thresholds reported herein. The rationale for large between-study 467 
discrepancies in absolute I-FABP concentrations are poorly understood, though are more 468 
likely attributable to analytical discrepancies (e.g. ELISA antibody, ELISA wash procedure, 469 
sample storage), than participant demographic (Treskes et al., 2017). The reliability of I-FABP 470 
at rest displayed moderate relative and acceptable absolute reliability. Following both EHSTs, 471 
I-FABP increased by approximately 50% or 0.800 ng·ml-1. This response is comparable to 472 
numerous similar duration/intensity exercise protocols, such as: 45-to-60 minutes of ~70% 473 
wattmax normothermic cycling (van Wijck et al., 2011, [61%, Δ 0.306 ng·ml-1] 2012, [61%; Δ 474 
0.179 ng·ml-1] and 20-30 minutes of ~80% VO2max running (Barberio et al., 2015 [46%, Δ 0.297 475 
ng·ml-1]; March et al., 2017 [72%; Δ 0.350 ng·ml-1]). In comparison, far greater elevations in I-476 
FABP have been shown following 90-120 minutes of moderate-intensity running performed 477 
in the heat (30°C; Morrison et al., 2014 [663%; Δ 0.203-0.806 ng·ml-1]; Snipe et al., 2017 478 
[288%, Δ 0.897 ng·ml-1]; 2018 [432%, Δ 1.230 ng·ml-1]. Given the high sensitivity of I-FABP to 479 
even minor GI injury, it is vital that known extraneous variables (e.g. prandial/hydration 480 
status, prior exercise) are tightly controlled prior to investigation. Whilst participants in the 481 
present study provided written conformity to all pre-trial controls, two participants’ resting I-482 
FABP concentrations appeared suspect to prior GI injury in one trial, which interestingly was 483 
unable to be detected by any other analyte. 484 
CLDN-3 is the principle biomarker of GI TJ integrity (Wells et al., 2017). Despite 485 
introduction as a TJ biomarker almost a decade ago, the biological relevance of elevated 486 
circulating CLDN-3 is still poorly understood. This includes the assessment of temporal 487 
reliability, which is currently unknown. In the present study, resting CLDN-3 concentrations 488 
were consistent with previous evidence (0.5-15 ng·ml-1) in healthy populations (Yeh et al., 489 
2013; Typpo et al., 2015). At rest, large inter-individual variation in CLDN-3 concentration was 490 
evident, meaning that relative reliability was almost uniform. Following both EHSTs, plasma 491 
CLDN-3 consistently increased by approximately 8-10%. This finding compares well to the only 492 
previous exercise study, where concentrations increased directly following a one hour 493 
moderate-intensity (70% VO2max) run in both temperate (22°C; 6.7 > 7.6 ng·ml-1) and hot 494 
(33°C; 6.6 > 8.2 ng·ml-1) ambient environments (Yeh et al., 2013). The clinical relevance of this 495 
small, transient increase in CLDN-3 following exercise is poorly understood, though is modest 496 
in comparison with the magnitude of increase (4-20 fold) shown acutely following major non-497 
abdominal surgery (Typpo et al., 2015; Habes et al., 2017). Promisingly, of all the GI barrier 498 
integrity biomarkers compared, CLDN-3 displayed the strongest relative and absolute 499 
reliability.  500 
LBP is a type-1 acute phase protein that responds to a wide-variety of microbial-501 
associated molecular patterns and is widely considered a stable indirect biomarker of 502 
bacterial endotoxin exposure (Dullah and Ongkudon, 2017). In the present study, resting LBP 503 
concentrations displayed showed moderate relative and good absolute reliability. These 504 
results are in support of one previous study, which found short-term (≤ 7 day) basal LBP 505 
responses to display moderate relative reliability (intraclass correlation coefficient = 0.61; 506 
Citronberg et al., 2016). In comparison, direct assessment of endotoxin appears to have weak 507 
basal temporal reliability, with an intra-individual CV of 22% reported over a similar 7-day 508 
period in basal conditions (Guy et al., 2017). Following the EHST, LBP was unchanged in both 509 
trials, with concentrations offering comparable levels of reliability compared to rest. Whilst 510 
the evidence is sparse regarding LBP responses to exercise, previous evidence has shown a 511 
minor elevation in LBP of 10-15% immediately following a fatiguing treadmill walk (4.5 km·h-512 
1) in the heat (40°C; 106 minutes; Selkirk et al., 2008), and 1 hour of moderate intensity (70% 513 
VO2max) treadmill running (Jonvik et al., 2019). A potential explanation for these discrepant 514 
findings likely relate to greater thermoregulatory/cardiovascular strain in previous studies. 515 
BactDNA is an emerging GI MT biomarker, given the recent characterisation of the 516 
blood microbiome and improvements in 16S PCR sensitivity (Paisse et al., 2016). In the 517 
present study, resting total 16S DNA concentrations displayed moderate relative and good 518 
absolute reliability. This finding is promising, given previous concerns that plasma bactDNA 519 
concentrations are susceptible to background sample contamination (Glassing et al., 2016). 520 
Quantification of total plasma 16S bacterial DNA in exercise settings has never been 521 
previously examined, though consistent with other MT biomarkers, the present results show 522 
total 16S bactDNA to be stable following moderate intensity exertional-heat stress. One 523 
criticism of total 16S bactDNA assessment, particularly in exercise settings, is a lack of GI 524 
specificity, with total concentrations influenced by factors including: DNase concentration 525 
(Velders et al., 2014) and 16S DNA contamination from other body/blood compartments 526 
(Paisse et al., 2016). To account for this error, one hypothetically improved method involves 527 
targeting a highly abundant GI genus such as Bacteroides (~30% of GI microbiota) and 528 
correcting for total 16S concentration (March et al., 2019). This method is particularly 529 
favourable given that the phyla Firmicutes and Bacteroidetes comprise >90% of the GI 530 
microbiome (Bacteroides; Huttenhower et al., 2012) and <5% of the plasma microbiome 531 
(Paisse et al., 2016). Utilising this hypothesis, March et al (2019) reported that the plasma 532 
Bacteroides/16S DNA ratio tended to increase (~25%; p = 0.07) following a one-hour 533 
moderate intensity (70% VO2max) run in the heat (30°C), though large inter-individual 534 
variability in responses were evident. In the present study, the Bacteroides/16S DNA ratio was 535 
unchanged following the EHST and appeared to be systematically lower post the EHST in trial 536 
two (but not the Δ). This systematic bias was unexpected given the uniformity of all other 537 
analytes assessed and the poor analytical reliability of this biomarker (e.g. mean duplicate CV 538 
= 17.5%). It is presently unclear whether the poor reliability of this measure has obscured a 539 
true effect of the EHST and/or the meaningfulness of this variability during more severe MT.  540 
Evidence directly comparing correlations between GI barrier integrity and/or MT 541 
biomarkers in exercise settings has been limited to date. Given general logistical constraints 542 
of the urine/plasma DSAT, the majority of relevant evidence has attempted to validate 543 
(correlate) this method against more practical GI barrier integrity biomarkers. These studies 544 
have generally shown significant, though weak correlations (r = 0.4-0.6) between basal 545 
corrected (Δ) DSAT (urine 5 hour) and I-FABP responses directly following minor exercise-546 
induced GI barrier integrity loss (van Wijck et al., 2011, 2012; March et al., 2017). In the 547 
present study, the DSAT did not correlate with any other GI integrity biomarkers. A potential 548 
explanation for this null finding might result from the lack of basal DSAT correction or the low 549 
overall severity of GI barrier integrity loss. In comparison, a small positive correlation was 550 
reported between I-FABP and CLDN-3. This finding is supportive of previous evidence showing 551 
urinary I-FABP and CLDN-3 to weakly correlate (r = 0.38) in patients with major non-abdominal 552 
surgery (Habes et al., 2017). The expression of CLDN-3 across multiple tissues might partially 553 
explain why this correlation was not stronger (Thuijls et al., 2010a). In general, no GI barrier 554 
integrity and MT biomarkers, except DSAT 150 and Δ LBP, were found to correlate. Previous 555 
exercise gastroenterology research has shown various combinations of these biomarkers to 556 
weakly correlate (r = 0.1-0.6; Yeh et al., 2013; Sessions et al., 2016; March et al., 2019) or not 557 
correlate (Karhu et al., 2017; Snipe et al., 2018). Several physiological (e.g. hepatic/immune 558 
microbial clearance, transcellular microbial translocation, GI microbial density) and analytical 559 
(e.g. exogenous sample contamination, inconsistent biomarker kinetics, DSAT/I-FABP limited 560 
to small GI integrity) factors all likely weaken this association (Wells et al, 2017).  561 
LIMITATIONS 562 
Despite implementation of a tightly controlled methodological design, which 563 
accounted for the majority of extraneous variables, the presented results were not without 564 
some limitations. First, the EHST was only able to evoke moderate GI barrier integrity loss and 565 
did not influence MT, potentially limiting the application of these findings in severe situations 566 
of GI barrier integrity loss. A previous systematic review has suggested an exercise induced 567 
hyperthermia threshold of 38.6°C Tcore for GI barrier integrity loss (DSAT, I-FABP and 568 
endotoxin) to be commonplace (>50% incidence) and of 39.0°C for GI barrier integrity loss to 569 
be universal (100% incidence; Pires et al., 2017). Consistently, previous research supports the 570 
notion that MT biomarkers (endotoxin) are less responsive to subtle alterations in GI barrier 571 
integrity that were otherwise detected by the DSAT or I-FABP following exercise (Snipe et al., 572 
2017, 2018; March et al., 2019). Positively, no GI barrier integrity or MT biomarker displayed 573 
statistical heteroscedasticity in this EHST model, suggestive that absolute reliability was not 574 
dependent upon the magnitude of biomarker response. Next, biomarker analysis was limited 575 
to a single time-point after the EHST (at termination), though this can be justified in that peak 576 
responses have been consistently shown to occur at this instance in comparable exertional-577 
heat stress interventions (e.g. I-FABP, Snipe et al., 2017; CLDN-3, Yeh et al., 2013; LBP, 578 
Moncada-Jimenez et al., 2010; Bact./16S, March et al., 2019). Third, there was statistically 579 
significant systematic bias for peak Tcore and Tbody responses, which were lower (0.17°C and 580 
0.18°C) following implementation of trial two. This result was not anticipated, given 581 
numerous previous studies showing a one week washout period to be sufficient in preventing 582 
carry-over (heat acclimation) effects following exertional-heat stress exposure of comparable 583 
severity (Barrett and Maughan, 1993; Willmott et al., 2015). The meaningfulness of this 584 
systematic bias did not appear to statistically influence any GI barrier integrity of MT 585 
biomarker. Finally, given neither a basal DSAT or urinary DSAT were performed, it was not 586 
possible to directly determine either than impact of the EHST on DSAT results or make 587 
comparisons between DSAT responses between biofluids. This decision was made to 588 
minimise participant time burden.  589 
CONCLUSION 590 
This is the first study to comprehensively assess the reliability of GI barrier integrity 591 
and/or microbial translocation biomarkers both at rest and following exertional (-heat) stress. 592 
Quantifying biomarker reliability is a vital step required to inform marker selection for 593 
application in laboratory and field settings. Each of the GI barrier integrity biomarkers 594 
assessed displayed moderate-to-good relative and acceptable absolute reliability both at rest 595 
and post the EHST. Serum DSAT responses had comparable reliability at two-separate time-596 
points following sugar-probe ingestion (90- and 150-minutes), though response kinetics 597 
displayed inconsistent time courses. I-FABP and CLDN-3 both increased following the EHST 598 
and their responses were found to weakly correlate. None of the selected MT biomarkers 599 
were elevated following the EHST, suggestive that a greater severity of GI barrier integrity loss 600 
is required for MT. LBP and total 16S DNA bothl demonstrated moderate-to-good relative and 601 
acceptable absolute reliability at both time-points. There was a weak correlation between 602 
LBP and total 16S post-EHST responses. Despite offering superior methodological rationale, 603 
Bacteroides DNA had unacceptable reliability. The findings of the present study have direct 604 
relevance for evaluating the efficacy of interventions to attenuate the rise in GI barrier 605 
integrity/MT when exercising in the heat. Such interventions might include exercise training, 606 
heat acclimatisation and nutritional supplementation. The findings of this study might also 607 
have value to the pharmaceutical industry, to quantify the efficacy of drugs to maintain GI 608 
barrier integrity, or to evaluate improvements in drugs that traditionally resulted in GI 609 
integrity loss.  610 
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Table 1. Participant demographic characteristics 824 
Measure Mean ± SD 
Age (years) 26 ± 5 
Height (m) 1.78 ± 0.06 
Body Mass (kg) 83.4 ± 12.6 
Physical Activity (h·week-1) 6 ± 3 
Body Fat (%) 16.1 ± 4.0 
V̇O2max (ml·kg-1·min-1) 49 ± 4 
 825 
 826 
Figure 1. Schematic illustration of the experimental measurement timings 827 
 828 
 829 
 830 
 831 
Figure 2. Whole-body physiological responses to repeated EHSTs: (A) = core temperature; 832 
(B) = mean skin temperature (n=13); (C) = mean body temperature (n=13); (D) = heart rate; 833 
(E) = thermal sensation; and (F) = rate of perceived exertion. Solid line = trial 1, broken line = 834 
trial 2. Significant overall effect of time (*p ≤ 0.05; ** p ≤ 0.01). 835 
 836 
 837 
Table 2. Relative and absolute reliability of whole-body physiological responses 838 
 Trial 1 
(SD) 
Trial 2 
(SD) 
p d r   CV  TEM 
  
Bias 
(LoA) 
Tcore  
(°C) Peak 
38.63 ± 
0.28 
38.46 ± 
0.37 
0.02 0.49 0.78** 0.5 0.14 0.17 ± 
0.46 
Tcore  
(°C) Mean 
37.87 ± 
0.19 
37.78 ± 
0.23 
0.09 0.43 0.68** 0.3 0.13 0.09 ± 
0.43 
Tcore  
(°C) Δ 
1.62 ± 
0.29 
1.55 ± 
0.44 
0.59 0.19 0.48 - 0.26 0.07 ± 
0.77 
Tskin  
(°C) Peak 
36.27 ± 
0.63 
36.13 ± 
0.65 
0.23 0.22 0.83** 0.6 0.27 0.13 ± 
0.74 
Tskin  
(°C) Mean 
35.75 ± 
0.44 
35.64 ± 
0.49 
0.13 0.24 0.83** 0.4 0.17 0.11 ± 
0.46  
Tskin  
(°C) Δ 
1.65 ± 
0.63 
1.46 ± 
0.65 
0.18 0.30 0.71** - 0.35 0.20 ± 
0.97 
Tbody  
(°C) Peak 
38.54 ± 
0.30 
38.36 ± 
0.37 
0.01 0.53 0.79** 0.4 0.16 0.18 ± 
0.44 
Tbody  
(°C) Mean 
37.83 ± 
0.20 
37.74 ± 
0.23 
0.08 0.42 0.70** 0.3 0.12 0.09 ± 
0.33 
Tbody 
(°C) Δ 
1.62 ± 
0.30 
1.49 ± 
0.40 
0.18 0.37 0.60* - 0.23 0.13 ± 
0.63 
HR (b·min-1) 
Peak 
164 ±     
13 
162 ±  
14 
0.19 0.15 0.93** 2.0 4 2 ± 11 
HR (b·min-1)  
Mean 
150 ±    
14 
148 ± 
13 
0.29 0.14 0.84** 2.8 5 2 ± 15 
HR (b·min-1)   
Δ 
90 ±        
11 
90 ±       
13 
0.99 0.00 0.88** - 4 0 ± 12 
RPE 
(AU) Peak 
16 ± 3 16 ± 3 0.99 0.00 0.92** 4.1 1 0 ± 3 
RPE  
(AU) Mean 
13 ± 2 13 ± 2 0.88 0.00 0.80** 5.2 1 0 ± 2 
RPE  
(AU) Δ 
6 ± 5 5 ± 3 0.95 0.24 0.72** - 2 0 ± 4 
TS  
(AU) Peak 
7.0 ±     
0.5 
7.0 ± 
0.5 
0.99 0.00 0.84** 4.8 0.5 0.0 ± 1.0 
TS  
(AU) Mean 
6.0 ±     
0.5 
5.5 ± 
0.5 
0.02 0.00 0.88** 3.2 0.0 0.5 ± 0.5 
TS  
(AU) Δ 
2.5 ±     
1.0 
2.5 ± 
0.5 
0.12 0.00 0.61* - 0.5 -0.5 ± 1.0 
* = significant correlation (p ≤ 0.05); ** = significant correlation (p ≤ 0.01) 839 
Table 3. Relative and absolute reliability of all GI barrier integrity biomarkers  840 
 Trial 1 
(SD) 
Trial 2 
(SD) 
p d r   CV  TEM 
  
Bias 
(LoA) 
Lactulose 
(mg·l-1) 90  
1.06 ± 
0.38 
0.90 ± 
0.43 
0.33 0.38 0.60* 21.3 0.263  0.151 ± 
0.730 
L-Rhamnose 
(mg·l-1) 90 
15.89 ± 
3.91 
15.85 ± 
3.13 
0.29 0.29 0.53 12.9 2.601  1.036 ± 
6.930 
DSAT (L/R) 
90  
0.028 ± 
0.012 
0.025 
±0.014 
0.17 0.23 0.77**  11.5 0.004  -0.003 ± 
0.011  
Lactulose 
(mg·l-1) 150  
0.97 ± 
0.48 
0.95 ± 
0.52 
0.53 0.05 0.71** 13.0 0.132  0.023 ± 
0.364 
L-Rhamnose 
(mg·l-1) 150 
12.01 ± 
2.95 
11.24 ± 
2.96 
0.09 0.27 0.86** 7.6 1.149  0.772 ± 
3.060 
DSAT (L/R) 
150  
0.033 ± 
0.015 
0.034 ± 
0.016 
0.37 0.06 0.69**  12.2 0.004  0.001 ± 
0.011 
I-FABP  
(ng·ml-1) Rest 
1.560 ± 
0.506 
1.691 ± 
0.555 
0.11 0.25 0.75** 11.1 0.304  -0.180 ± 
0.746 
I-FABP 
(ng·ml-1) Post 
2.394 ± 
0.731 
2.467 ± 
0.875 
0.63 0.09 0.80**  12.1 0.376  -0.073 ± 
1.040  
I-FABP  
(ng·ml-1) Δ 
0.834 ± 
0.445 
0.776 ± 
0.489 
0.65 0.12 0.65**  - 0.278  0.058 ± 
0.772 
CLDN-3  
(ng·ml-1) Rest 
6.205 ± 
4.382 
5.971 ± 
4.062 
0.17 0.06 0.99**  6.8 0.423     0.233 ± 
1.172 
CLDN-3  
(ng·ml-1) Post 
6.592 ± 
4.770 
6.323 ± 
4.270 
0.34 0.06 0.99**  4.9 0.485   0.181 ± 
1.341 
CLDN-3 
(ng·ml-1) Δ 
0.317 ± 
0.586 
0.371 ± 
0.508 
0.68 0.10 0.62*  - 0.342  -0.055 ± 
0.948 
* = significant correlation (p ≤ 0.05); ** = significant correlation (p ≤ 0.01) 841 
 842 
 843 
 844 
 845 
 846 
 847 
Figure 3. GI barrier integrity responses to EHST trial 1 and trial 2: (A) = L/R ratio at 90 848 
minutes; (C) = L/R ratio at 150 minutes; (E) I-FABP (n=13); and (G) = CLDN-3. Significant 849 
overall effect of time (*p ≤ 0.05; ** p ≤ 0.01). Bland-Altman mean bias and 95% LoA 850 
between post EHST trial 1 and trial 2: (B) = L/R ratio at 90- and (D) 150- minutes; (F) I-FABP 851 
(n=13); and (H) = CLDN-3 852 
Table 4. Relative and absolute reliability of all GI barrier integrity biomarkers  853 
 Trial 1 
(SD) 
Trial 2 
(SD) 
p d r   CV  TEM 
  
Bias 
(LoA) 
LBP (µg·ml-1)     
Rest 
2.625 ± 
0.993 
2.564 ± 
0.871 
0.79 0.07 0.85**  10.0 0.378  0.061 ± 
1.048 
LBP (µg·ml-1)    
Post 
2.617 ± 
1.080 
2.650 ± 
0.885 
0.59 0.03 0.85**  9.2 0.420  -0.033 
± 1.166 
LBP (µg·ml-1)         
Δ 
-0.008 
± 0.250 
0.086 ± 
0.232 
0.38 0.39 -0.16  - 0.260  -0.094 
± 0.721 
16S DNA (pg·µl-1) 
Rest 
1.43 ± 
0.60 
1.44 ± 
0.65 
0.79 0.02 0.87** 8.1 0.19 -0.02 ± 
0.49 
16S DNA (pg·µl-1) 
Post 
1.47 ± 
0.70 
1.52 ± 
0.73 
0.45 0.07 0.82** 9.5 0.15 -0.05 ± 
0.40 
16S DNA (pg·µl-1) 
Δ  
0.043 ± 
0.28 
0.08 ± 
0.40 
0.72 0.10 0.56* - 0.24 -0.03 ± 
0.65 
Bact. DNA 
(copies·µl-1) Rest 
0.142 ± 
0.116 
0.102 ± 
0.089 
0.19 0.39 0.14 55.0 0.067 0.040 ± 
0.186 
Bact. DNA 
(copies·µl-1) Post 
0.202 ± 
0.132 
0.115 ± 
0.106 
0.04* 0.73 0.14 56.3 0.104 0.087 ± 
0.287 
Bact. DNA 
(copies·µl-1) Δ  
0.059 ± 
0.149 
0.013 ± 
0.140 
0.22 0.32 0.61* - 0.091 0.047 ± 
0.250 
Bact./16S DNA 
Rest 
96.08 ± 
59.31 
74.10 ± 
52.82 
0.31 0.39 0.13 60.2 52.49 -0.019 
± 0.348 
Bact./16S DNA 
Post 
143.41 
± 90.73 
91.83± 
124.76 
0.07 0.47 0.20 54.7 88.18 0.032 ± 
0.347 
Bact./16S DNA Δ 47.32 ± 
95.74 
17.74 ± 
138.78 
0.35 0.25 0.69* - 76.88 0.052 ± 
0.378 
* = significant correlation (p ≤ 0.05); ** = significant correlation (p ≤ 0.01) 854 
 855 
 856 
 857 
 858 
 859 
 860 
Figure 4. GI MT responses to EHST trial 1 and trial 2: (A) = LBP; (C) total 16S bacterial DNA 861 
(n=13); (E) = Bacteroides DNA; and (G) = Bacteroides/total 16s bacterial DNA (n=13). 862 
Significant overall effect of trial (+ p ≤ 0.05). Bland-Altman mean bias and 95% LoA between 863 
post EHST trial 1 and trial 2: (B) = LBP; (D) = total 16S bacterial DNA (n=13); (F) Bacteroides 864 
DNA (n=13); and (H) = Bacteroides/total 16s bacterial DNA (n=13). 865 
 866 
